Select your Market
-
- Algeria
- Angola
- Benin
- Botswana
- Burkina Faso
- Burundi
- Cameroon
- Cape Verde
- Central African Republic
- Chad
- Comoros
- Congo
- Congo Democratic Republic
- Djibouti
- Egypt
- Equatorial Guinea
- Eritrea
- Ethiopia
- Gabon
- Gambia
- Ghana
- Guinea
- Guinea-Bissau
- Ivory Coast
- Kenya
- Lesotho
- Liberia
- Libya
- Madagascar
- Malawi
- Mauritania
- Mauritius
- Morocco
- Mozambique
- Namibia
- Niger
- Nigeria
- Reunion Islands
- Rwanda
- Saint Helena
- São Tomé and Príncipe
- Senegal
- Seychelles
- Sierra Leone
- Somalia
- South Africa
- Sudan
- Swaziland
- Tanzania
- Togo
- Tunisia
- Uganda
- Zambia
- Zimbabwe
-
- Albania
- Austria
- Baltic Region
- Belarus
- Belgium
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Finland
- France
- Germany
- Greece
- Hungary
- Ireland
- Italy
- Latvia
- Lithuania
- Luxembourg
- Netherlands
- North Macedonia
- Norway
- Poland
- Portugal
- Romania
- Russian Federation
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Türkiye
- Ukraine
- United Kingdom
Overview
- Net sales increase by 8.1%, driven by double-digit growth in Healthcare and Life Science
- EBITDA pre up by 15.4%
- Forecast for sales and earnings raised following Versum acquisition
In the third quarter, we continued to resolutely implement our strategy. We substantially increased sales and earnings.
Quarterly Statement Q3 2019
Merck KGaA, Darmstadt, Germany Generates Profitable Growth in Q3 2019
PDF Download
Video: Financial Results Q3 2019
Overview of our third quarter financial results 2019.
Watch the videoRelated News
View All News-
Press Releases
Merck KGaA, Darmstadt, Germany Generates Profitable Growth in Q3 2019
Merck KGaA, Darmstadt, Germany generated strong organic sales growth and benefited from positive foreign exchange effects in the third quarter of 2019.
2019/11/14
-
Gangolf Schrimpf
Financial Communications
+49 6151 72-9591+49 6151 72-3138
-
Constantin Fest
Head of Investor Relations
+49 6151 72-5271+49 6151 72 91-5271